Apoaequorin and curcumin containing compositions and methods

Abstract

To provide compositions and methods for treating symptoms and disorders, for example, mental disorder, anxiety, cognitive function, sleep quality, energy quality, mood quality, memory quality, or pain.SOLUTION: Provided is a composition for improving human health conditions, comprising (a) an effective amount of apoaequorin, (b) an effective amount of curcumin, and (c) an acceptable carrier.SELECTED DRAWING: Figure 1

Description

[Technical Field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This international application is a continuation of U.S. Provisional Application No. 62 / 980,785, filed February 24, 2020. No. 60 / 199,992, filed on Oct. 1, 2003, which claims the benefit of provisional application no. 11 / 1992, filed on Oct. 1, 2003, which provisional application is incorporated herein by reference.

[0002] <Statement regarding federally funded research and development> Not applicable.

[0003] The present invention relates generally to compositions useful for maintaining human health. In particular, the present invention relates to apo The present invention relates to a dietary supplement composition containing aequorin and curcumin. Summary of the Invention

[0004] The present invention provides a method for improving and / or maintaining human health that goes beyond conventional compositions and methods. Such compositions provide a variety of benefits for administration to a subject by a variety of routes. The present invention includes a formulation of apoaequorin and curcumin in combination with an acceptable carrier for the treatment of rheumatoid arthritis.

[0005] Thus, the present invention provides an effective amount of apoaequorin and In certain embodiments, the present invention relates to a curcumin-containing composition, in combination with an acceptable carrier. The present invention relates to a dietary supplement composition comprising an effective amount of apoaequorin and curcumin combined. In certain embodiments, the dietary supplement composition comprises, in addition to apoaequorin and curcumin: Nutrients, such as immune enhancers, anti-inflammatory agents, antioxidants, antivirals, or mixtures thereof. and at least one other ingredient recognized to provide nutritional benefits. The apoaequorin and curcumin compositions are available in the form of tablets, capsules, solutions, suspensions, A unit dose selected from a syrup, a drink, or an oral or ophthalmic formulation. It is available in the form of sage.

[0006] In another aspect, the present invention provides a method for treating conditions or disorders associated with calcium imbalance. The method comprises administering to a subject in need of such treatment an effective amount of apoaequorin. This involves administering acetaminophen and curcumin.

[0007] The method according to the present invention may be used to treat a range of conditions including psychiatric disorders, anxiety, cognitive function, sleep quality, energy quality, mood quality, pain, and the like. A wide variety of symptoms related to human health, including but not limited to memory quality In certain embodiments, the condition or disorder is a neurodevelopmental disorder. It is involved in excitability, muscle contraction, membrane permeability, cell division, hormone secretion, bone mineralization, or cell death after ischemia. In such a method, apoaequorin and curcumin are preferred. The compound is administered to the subject in the form of a dietary supplement composition.

[0008] In yet another embodiment, the present invention provides a method for treating a malaria parathyroidectomy (MSP) in a subject administered a dietary supplement composition. and a method for producing a dietary supplement composition for treating a health condition or disorder. Examples of conditions treated with such compositions include the use of poequorin and curcumin. Symptoms or disorders indicative of mental disorders, anxiety, cognitive function, sleep, energy, mood, pain, or memory Includes those related to.

[0009] Thus, the present invention further provides a method for treating, for example, psychiatric disorders, anxiety, cognitive function, sleep, Symptoms or disorders in a subject, including symptoms or disorders related to vitality, mood, pain, or memory The present invention relates to apoaequorin and curcumin for use in the treatment of

[0010] The present invention overcomes conventional combinations in that it provides an overall improvement in the mental and physical well-being of a subject. The present invention provides various advantages over the compositions and methods.

[0011] Other objects, features and advantages of the present invention will become apparent from a reading of the specification and claims. It will be. [Brief explanation of the drawings]

[0012] [Figure 1] Graphs showing percent change from baseline in scores in the domains of overall quality of sleep, energy, mood, pain, and general well-being from day 0 to day 90. [Figure 2] This graph shows data from 56 participants taking apoaequorin (10 mg) daily. Participants were assessed for 8 to 30 days. Memory assessments showed statistically significant improvements in memory after 30 days (hp<0.05). 57% of participants had improved overall memory, 51% had improved information retention, 84% had improved driving direction memory, and 66% had improved word recall. N=56, 66% female, 34% male, mean age=56, ranging from 20 to 78 years. [Figure 3] Graph showing percent change from baseline in scores from a standardized cognitive battery questionnaire from day 0 to day 90. DETAILED DESCRIPTION OF THE INVENTION

[0013] I. General matters Before describing the materials and methods of the present invention, it is important to note that the present invention is not limited to the specific methodology and methods described. It should be understood that the materials are not limiting and may vary. The terminology used herein is intended to describe particular embodiments only. and is not intended to limit the scope of the invention, which is limited only by the claims. It should also be understood that this is not the case.

[0014] As used in this specification and claims, the singular forms "a," "an," and " Please note that "the" includes plural references unless the context clearly indicates otherwise. Similarly, "a" (or "an"), "one or more," and "at least one" The terms "equipment" and "equipment" can be used interchangeably in this specification. The terms "comprises," "includes," and "has" may be used interchangeably. It should be noted that:

[0015] Unless otherwise defined, all technical and scientific terms used herein The meanings of the terms "a", "b", and "c" have the same meaning as commonly understood by those skilled in the art to which the present invention pertains. Any methods and materials similar or equivalent to those described herein may be used in practice or testing. Although any method and material can be used, suitable methods and materials are described below. All publications and patents specifically mentioned in this document are reported among the publications that may be used in connection with the invention. for all purposes, including the description and disclosure of the chemicals, instruments, statistical analyses and methodologies used All references cited herein are hereby incorporated by reference. The documents should be taken as indicative of the level of skill of those skilled in the art. without further elaboration, nor shall any person be liable for any loss whatsoever suffered by any person whatsoever arising from or in connection with the present invention. should not be interpreted as

[0016] II. The present invention Aequorin is a photoprotein originally isolated from luminescent jellyfish and other marine organisms. The aequorin complex is a 22,285 dalton apoaequorin. It consists of a phosphoprotein, molecular oxygen, and the light-emitting molecule coelenterazine. This complex contains three C a 2+ When coelenterazine binds to coelenteramide, it is oxidized to coelenterazine and coelenteramide. Carbon dioxide and blue light are released. Aequorin is not transported away or secreted by cells. They are not compartmentalized or sequestered within cells. Therefore, aequorin measurements are based on the Ca concentration, which occurs over a relatively long period of time. 2+ To detect changes in In some experimental systems, aequorin luminescence persists for several hours after cell loading. Aequorin was detectable several days after administration. Furthermore, aequorin does not disrupt cell function or embryonic development. It is further known that

[0017] The aequorin complex contains its Ca lf Intracellular Ca dependent luminescence 2+ Indicator and Aequorea victoria has been widely used as a jellyfish. Lin (1) investigated the secretory response of single adrenal chromaffin cells to nicotinic cholinergic agonists. (2) Ca in myocardial injury 2+ To clarify the role of release, (3) Ca at fertilization 2+ (4) in developing chicken myoblasts to demonstrate the massive release of Sarcoplasmic reticulum Ca 2+ (5) To investigate the tunability of pump expression, only 3 picoliters It is particularly used to calibrate micropipettes for injection volumes of 1000 µL.

[0018] Apoaequorin has a molecular weight of approximately 22 kDa. can be used to regenerate aequorin by reducing the disulfide bonds in Calcium-loaded apoaequorin binds to the substrate The same compact scaffold and overall folding as the unreacted photoprotein, including retains the pattern.

[0019] Conventional purification of aequorin from Aequorea victoria requires laborious extraction work. Also, sometimes the resulting formulation is substantially heterogeneous or toxic to the organism under investigation. Typically, about 125 mg of purified photoprotein is obtained from 2 tons of jellyfish. In contrast, recombinant aequorin is preferably prepared by genetically engineering Eseh Purification of apoaequorin from Escherichia coli followed by the production of pure coelenterazine This invention is produced by reconstituting the aequorin complex in vitro using Apoaequorin has been described as being useful, but this is not a purified synthetic apoaequorin known to those skilled in the art. These compounds are commercially available through pharmaceutical and / or synthetic methods. Y. Sakaki, F. Tsuji, “High level expression and purification of apoaequorin” (1991), P rotein Expression and Purification 2,122 -126.

[0020] The present invention provides a method for administering a composition containing apoaequorin and curcumin to a subject, thereby improving mental function. Mental disorders, anxiety, cognitive function, sleep quality, energy quality, mood quality, pain, memory quality (but these Curcumin (diferuloylmethane; 1 ,7-Bis[4-hydroxy-3-methoxyphenyl]-1,6-heptadiene-3,5 -dione) is a liposoluble molecule, a hydrophobic polyphenol derivative. The known identifier for amine is CAS number 458-37-7. Its chemical formula is CH 20O6, the molar mass is 368.39 g / mol, and the melting point is 183°C (361°F). ;456K).

[0021] Curcuminoids, bisdemethoxycurcumin, demethoxycurcumin, and tetrahydrofuran Curcumin and its monomethoxy and dimethoxy derivatives, known as locurcumin is the main component of curcumin preparations obtained from the extraction process. Commercially available curcumin is Approximately 77% diferuloylmethane, 17% demethoxycurcumin and 17% bisdemethan It may contain 6% xycurcumin. Curcumin is derived from turmeric (Curcuma longa). (Turmeric) from the dried and ground rhizome of the plant by solvent extraction Turmeric has historically been used in various forms in Indian Ayurvedic medicine. It has been used to treat a variety of disorders, but it wasn't until the 20th century that scientific research discovered its effectiveness. Lucumin was identified as the factor responsible for most of its biological activity.

[0022] Curcumin has been the subject of numerous preclinical and clinical investigations, highlighting its anti-inflammatory and antioxidant properties. Curcumin has the ability to regulate cellular oxidative balance and It is mediated by a number of mechanisms in various ways, and in particular by a series of factors (C Inhibits OX1 and 2, TNF, lipoxygenase, and interferon-γ. In vitro, its efficacy as an antitumor agent has been demonstrated (Bengmar k S.,JPEN,2006,30(1):45-51).

[0023] Curcumin (including derivatives of curcumin such as its esters that act as prodrugs) (which generally occurs in smaller proportions with other curcumin complexes, such as curcumin complexes) It can be obtained from the lucminoids (or related compounds) or its bioavailability Biocurcumin (BCM-95®) in association with oils and polymers that increase the )) (US20070148263) or can be obtained as Piperi (Shobha et al., Planta Med, 1998, 64:353-56) They are often formulated together or with other compounds to stabilize the molecule and provide better bioavailability. Lecithin and / or fatty acids and / or triglycerides and optionally Twee As micro- or nano-emulsions / nano-dispersions where surfactants such as n80 are used Obtained.

[0024] Diarylheptanoids are also compounds to which curcuminoids (e.g., curcumin) belong. It should also be recognized that ginger can be considered a type of compound. Other similar diarylheptanoids, such as arylheptanoids, include curcuminoids ( For example, curcumin). Although curcumin) has been described in detail, other diarylheptanoids may have similar or identical biological properties and effects, and may be used in combination with other compounds as described herein. and can be included in suitable compositions and used in the methods of treatment as described herein. It will be recognized that

[0025] Furthermore, both older and younger people, including students, construction workers, drivers, pilots, Especially in everyday jobs including doctors, salespeople, executives, housewives and "highly professional" People who require high levels of memory and attention, and those prone to mental instability and dramatic mood swings Concentration and learning ability in people who are under stress or mental or daily stress There has been growing interest in developing therapeutic compounds that can be used to improve memory and attention. Therapeutic drugs that can bring about a balanced mental state are effective in treating stressful and hardship situations. contribute to a more productive life for the majority of people living a high-performance life. Deaf.

[0026] Thus, in certain embodiments, the methods of the present invention are directed to improving attention span. In another embodiment, the method comprises administering apoaequorin and curcumin as the active ingredients. In this regard, the present invention provides apoaequorin and curcumin-containing compositions in combination with known therapeutic or includes administering in combination with one or more additional agents having nutraceutical value. A particularly preferred use of apoaequorin and curcumin is to improve attention span. in the treatment of one or more of the associated conditions and disorders.

[0027] As used herein, the terms "vigilance," "sustained attention," and "attention span" are used interchangeably. The term refers to an individual's ability to pay attention to a stimulus or object over a period of time. In other words, it is the ability to maintain concentration and vigilance over a period of time.

[0028] As used herein, the term "treatment" includes prophylactic and damage-reducing treatment. As used herein, the terms "reduce," "mitigate," "suppress," and "prevent" The word has its commonly understood meaning of lessening or reducing. When used in this context, the term "progress" refers to an increase in extent or severity, progression, growth, or worsening. As used herein, the term "relapse" means a relapse of a disorder after a temporary recovery. It means the return of harm.

[0029] As used herein, the term "administration" refers to administering to a patient, tissue, organ, or cell. As used herein, the term "apoaequorin" refers to contacting a protein with apoaequorin and curcumin. When administered, administration may be in vitro, i.e., in a test tube, or in vivo. That is, in vivo, for example in human cells or tissues. In this regard, the present invention includes administering to a patient or subject a formulation or composition useful in the present invention. "Patient" or "subject," as used equivalently herein, refers to (1) apoaequorin have calcium imbalance-related disorders that can be successfully or treatable with the administration of benzodiazepine and curcumin or (2) calcium imbalance, which can be prevented by administration of apoaequorin and curcumin. It refers to a human being, preferably a mammal, susceptible to a balance-related disorder.

[0030] As used herein, the terms "effective amount" and "therapeutically effective amount" include amounts that do not include toxic, to produce the desired therapeutic response without undue adverse side effects such as irritation or allergic reaction A specific "effective amount" refers to an amount of an active agent sufficient to treat the particular condition being treated, the state of the patient, and the amount of the active agent. the animal's condition, the species of animal being treated, the duration of treatment, the nature of concurrent therapy (if any), and the type of may vary depending on factors such as the particular formulation used, and the structure of the compound or its derivatives. In this case, the difference in the subjects' response to the combination compared to subjects who did not receive the combination is clear. Prevention of mental disorders, anxiety, cognitive function, sleep quality, energy quality, mood quality, pain, memory quality, recovery An amount is therapeutically effective if it results in one or more of recovery, stabilization, or improvement. In certain embodiments, the condition or disorder may be neurological, muscular, or both. Physiologically related to contraction, membrane permeability, cell division, hormone secretion, bone mineralization, or post-ischemic cell death The optimal effective amount can be readily determined by one skilled in the art using routine experimentation.

[0031] In certain preferred compositions for oral administration to a subject, apoaequorin is present in an amount of about 10 The dosage is 20 mg to 80 mg / dose, preferably 20 mg to 70 mg / dose. It is more preferably formulated into a formulation at a dosage of 30 mg to 60 mg per dose. The compound is formulated in a dosage of about 80 mg to 1200 mg per dose, and the dosage is adjusted to the patient's preferred dose. The dosage is approximately 600 mg to 800 mg per dose.

[0032] Conventional additives, such as diluents, ligands, buffers, sweeteners, flavors, colors, solubilizers Agents, disintegrants, wetting agents and other commonly used additives can be added to the formulation. Suitable flavorings include natural flavors, artificial flavors, and mints such as peppermint. , menthol, artificial vanilla, cinnamon, and various fruit flavors, both individually and in mixtures. Flavorings are usually used in different amounts depending on the individual flavor, e.g. , can range in amounts from about 0.5% to about 3% by weight of the final composition.

[0033] When sweeteners are used, the present invention includes those known in the art, including both natural and artificial sweeteners. It is intended to include any of the commonly known sweeteners. Accordingly, additional sweeteners may include the following non-sweeteners: Can be selected from a non-exhaustive list: sucrose, glucose (corn syrup), invert sugar, fulvastatin sugars such as lactose and mixtures thereof; saccharin and its sodium salts or calcium salts; various salts such as ammonium salts; cyclamic acid and its sodium salts; aspartic acid Dipeptide sweeteners such as glycerol; dihydrochalcones; glycyrrhizin; stevia (steviolone) sid); as well as sorbitol, sorbitol syrup, mannitol, xylitol, etc. Sugar alcohols, as additional sweeteners, are listed in U.S. Patent No. Re 26,959. Non-fermentable sugar substitutes (hydrogenated starch hydrolysates) are also contemplated. Synthetic sweetener 3,6-dihydro-6-methyl-1-isothiazolinone as described in No. 01,017.7 -2,3-oxathiazin-4-one-2,2-dioxide, especially its potassium salt (acetonitrile) Sulfam K), sodium salts and calcium salts are also contemplated. Generally, the amount of sweetener is: It depends on the type of sweetener and the desired taste of the final product. For example, natural sweeteners have a sweetness of about 5 times the sweetness of 10 ... Sweeteners may be used in amounts up to about 1% by weight, while artificial sweeteners may be used in amounts up to about 1% by weight. It is possible.

[0034] Colorants useful in the present invention are in amounts up to about 1% by weight, preferably up to about 0.6% by weight. Colorants also include pigments such as titanium dioxide, which can be incorporated into food, pharmaceuticals, and Suitable for cosmetic and cosmetic use and may contain other dyes such as those known as FD&C dyes. Materials acceptable for the above range of use are preferably water-soluble. Examples include: FD&C Blue No. 1, the disodium salt of 5,5'-indigotindisulfonic acid FD&C Green No. 2 is an indigo dye. The dyes known as .1 include triphenylmethane dyes, such as 4-[4-N-ethyl-p -sulfobenzylamino)diphenylmethylene][1-(N-ethyl-Np-sulfonyl It is the monosodium salt of (methylbenzyl)-2,5-cyclohexadienimine. All F A complete listing of D&C and D&C dyes and their corresponding chemical structures is available from Kirk-Othmer Encyclopedia of Chemical Technology,Vol. ume 5, Pages 857-884, the contents of which are incorporated herein by reference. It shall be included in the

[0035] The compositions of the present invention further include liquid or lyophilized or otherwise dried formulations, Various buffer contents (e.g., Tris-HCl, acetate, phosphate), pH and ions Strong diluents, additives such as albumin or gelatin to prevent absorption onto surfaces, washing agents detergents (e.g., Tween 20, Tween 80, Pluronic F68, bile salts) , solubilizers (e.g., glycerol, polyethyleneglycerol), antioxidants (e.g., ascorbic acid, sodium metabisulfite), preservatives (e.g., thimerosal, benzyl alcohol, parabens), bulking agents or tonicity modifiers (e.g., lactose, mannitol) , covalent attachment of polymers such as polyethylene glycol to proteins, complexation with metal ions Bodybuilding or polymeric compounds such as polylactic acid, polyglycolic acid or hydrogels Incorporation of materials into or onto particulate formulations, or in liposomes, microemulsions, Materials on micelles, lamellar or multilamellar vesicles, erythrocyte ghosts or spheroplasts Such compositions are characterized by their physical state, solubility, stability, and in vivo Sustained release compositions or Sustained release compositions include lipophilic depot (eg, fatty acids, waxes, oils) formulations.

[0036] The formulation of compositions that contain active ingredients is well understood in the art. are often mixed with excipients that are pharmaceutically acceptable and compatible with the active ingredient. The additives include, for example, water, saline, dextrose, glycerol, ethanol, etc. or any combination thereof. Additionally, the composition may contain a moisturizing agent that enhances the effectiveness of the active ingredient. Minor amounts of auxiliary substances, such as wetting or emulsifying agents, pH buffering agents, and the like, may be contained.

[0037] The active ingredient may be formulated into the composition in the form of a neutralized pharmaceutically acceptable salt. Pharmaceutically acceptable salts include acid addition salts, such as those obtained with hydrochloric or phosphoric acid. It is formed with inorganic acids such as acetic acid, tartaric acid, and mandelic acid, or with organic acids such as acetic acid, tartaric acid, and mandelic acid. Salts formed from the silyl group include, for example, sodium, potassium, ammonium, calcium, or or ferric hydroxide, and inorganic bases such as isopropylamine, trimethylamine, 2 It can also be obtained from organic bases such as ethylaminoethanol, histidine, and procaine. Cut.

[0038] The salts of the active ingredients are preferably pharmaceutically acceptable salts, although other salts are also within the scope of the present invention. or a pharmaceutically acceptable salt thereof. Suitable pharmaceutically acceptable salts can be prepared, for example, by dissolving a solution of the active ingredient in hydrochloric acid, sulfuric acid, Methanesulfonic acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, oxalic acid, kue by mixing with a solution of a pharmaceutically acceptable acid such as carboxylic acid, tartaric acid, carbonic acid or phosphoric acid. This includes acid addition salts which may be formed by the addition of

[0039] Furthermore, for purposes of this specification, "food supplement" includes any food supplement for the prevention and / or treatment of disease. A food or portion of a food that provides a medical health benefit. contains only apoaequorin and curcumin as active ingredients, or alternatively, Coenzyme Q10, a vitamin that can supplement the diet by increasing the total absorption of substances in the body It also contains a mixture of nutritional supplements including iron, minerals, herbs, amino acids, etc. Good too.

[0040] Therefore, the present invention provides a food supplement composition containing apoaequorin and curcumin. The present invention provides a method for providing a health benefit to a patient, comprising administering to an animal a composition comprising: The compositions will generally include an "acceptable carrier," which as used herein means any suitable carrier for oral delivery, including the pharmaceutically acceptable carriers described above suitable for oral route; Thus, the present invention provides a more favorable mechanism for oral delivery of drugs to patients. Provides a rhythm.

[0041] In certain embodiments, the compositions according to the invention are immunosuppressants, as defined on a functional basis. including dietary supplements containing anti-inflammatory agents, antioxidants, antivirals or mixtures thereof. nothing.

[0042] Immune enhancers and / or antiviral agents are useful in promoting wound healing and improving immune function. They contain extracts from cornflower or Echinacea herb, Sambuca Extracts from herbs of the Astragalus genus and extracts of Goldenseal. Herbs of the Astragalus genus are also Astragalus, in either its natural or processed form, is an effective immune enhancer. Stimulates the development of stem cells and lymphoid tissue-active immune cells. Zinc, as well as zinc gluconate and and its bioactive salts, such as zinc acetate, also act as immune boosters in the treatment of the common cold. do.

[0043] Antioxidants include the natural sulfur-containing amino acid allicin, which increases the levels of antioxidant enzymes in the blood. Herbs or herbal extracts containing allicin, such as garlic, are also effective. Catechin and extracts of herbs such as green tea that contain catechins are also effective antioxidants. Extracts of Astragalus also exhibit antioxidant activity. Quercetin, hesperidin, and ruchi Bioflavonoids, such as flavonoids and mixtures thereof, are also effective as antioxidants. The main beneficial role of vitamin C in the body may be to protect it from oxidation. The more vitamin C or ascorbic acid becomes available to the body.

[0044] Bioflavonoids such as quercetin are also effective anti-inflammatory agents and may be used in the compositions of the present invention. Anti-inflammatory herbal supplements and herbal supplements derived from plants or herbs can be used as such. Anti-inflammatory compounds may also be used as anti-inflammatory agents in the compositions of the present invention. These include bromolein, a proteolytic enzyme found in pineapple, and bromolein, a proteolytic enzyme found in tea and peanuts. Extract of Kusa and turmeric, turmeric extract or turmeric isolated It contains the yellow pigment curcumin.

[0045] Another food supplement that can be used in the present invention is ginger, derived from the herb Zingiberaceae. This is due to the cardiotonic activity of compounds such as gingerol and the related compound shogaol. and have been found to provide benefit in the treatment of vertigo and vestibular disorders. Ginger is also effective in treating nausea and other stomach ailments.

[0046] Supplements that aid in the reconstruction of soft tissue structures, especially cartilage, may be beneficial for the treatment of arthritis and other joint disorders. Useful in compositions for treating pain. Glucosamine, glucosamine sulfate, cocosamine sulfate, Androitin can be obtained from a variety of sources, such as elk velvet antler. Marine lipid complex, omega-3 fatty acid complex, and fish oil may also be useful in treating pain associated with arthritis. It is known that:

[0047] Food supplements that are useful in treating migraines include feverfew and ginkgo biloba. The main active ingredient in is parthenolide, a sesquiterpene lactone, which acts as a vasodilator. It inhibits the secretion of prostaglandins, which cause pain through vasospastic activity in the blood. Fish oil also exhibits anti-inflammatory properties due to its platelet stabilizing and anti-vasospastic properties. It may also be useful in treating migraines. Ginkgo biloba herb also stabilizes arteries and It helps treat migraines by improving blood circulation.

[0048] Some of the supplements listed above have been described for their pharmacological effects, while others Additives may also be used in the present invention, and their effects are well documented in the scientific literature. It has been done.

[0049] The invention will be more fully understood in light of the following non-limiting examples.

[0050] <Example> [Example 1] Administration of apoaequorin over a 90-day time course improved quality of life in the study subjects. Tee of life improves.

[0051] This analysis was an open-label study of 32 patients over 90 days and evaluated overall sleep quality. The results show improvements in performance, energy, mood, pain and overall well-being. Changes in performance were measured using a standardized questionnaire battery. These included qualitative cognitive tests. The survey included assessment of sleep quality, headache quality, and quality of life questions. No participants discontinued the study due to adverse events. It was.

[0052] The results shown in Figure 1 show the percentage change from baseline in the scores of the above areas. The memory scores are excluded for a separate graph. The graph is shown as marks 1, 2, 3, 4 and 5 versus days 0 to 90. Shown to improve overall quality of sleep, energy, mood, pain and overall well-being. The line was known from the pre-survey stage.

[0053] [Example 2] Administration of apoaequorin over a 30-day time course improved quality of life in the study subjects. Tee of life improves.

[0054] The study was an open-label study involving 56 participants over a 30-day period. Changes in performance were measured using a memory screening tool. The study found improvements in memory performance as early as day 8, but by day 30 Statistically greater improvements were observed. No participants discontinued the study due to adverse events. Ta.

[0055] [Example 3] Administration of apoaequorin over a 90-day time course improved cognitive performance in study subjects. Strength improves.

[0056] The analysis showed cognitive improvements in an open-label study of 32 patients. Changes in performance were measured using a standardized cognitive battery. Cognitive improvement was observed as early as day 30 and days 60-90. There was generally greater improvement in patients with steroid use. No participants discontinued the study due to adverse events. The results shown in Figure 3 demonstrate that cognitive ability scores improved significantly from baseline. (Note) More than 51% of participants experienced improvements in cognitive ability.

[0057] The examples and embodiments described herein are for illustrative purposes only and Various modifications or alterations to the present invention will be suggested to those skilled in the art and will fall within the spirit and scope of the present application and the appended claims. It is understood that all such modifications and variations are to be construed as falling within the scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes. It shall be included.

[0058] Other embodiments and uses of the invention are contemplated by consideration of the specification and practice of the invention disclosed herein. All journal citations and US / foreign patents are incorporated herein by reference. All references cited herein for any reason, including patents and patent applications, are hereby incorporated by reference. The present invention relates to a method for producing a medicament for the treatment of a pulmonary arthritis, comprising: It is not intended to be limited to the specific reagents, formulations, reaction conditions, etc., illustrated and described herein. and includes these modifications and is within the scope of the following claims. It is understood.

Claims

1. 1. A composition for improving human health, comprising: (a) an effective amount of apoaequorin; (b) an effective amount of curcumin; and (c) an acceptable carrier.

2. further comprising an immune enhancing agent, an anti-inflammatory agent, an antioxidant, an antiviral agent, or a mixture thereof; The composition of claim 1.

3. The composition may be a tablet, capsule, solution, suspension, syrup, beverage, or oral or ophthalmic formulation.

3. The composition according to claim 1 or 2, in the form of a single dose selected from a pharmaceutical formulation for use in a patient.

4. The composition according to any one of claims 1 to 3, wherein the composition is in the form of a dietary supplement composition. composition.

5. A method for improving the health of a human, comprising administering to a subject in need of such treatment a A method comprising administering the composition of any one of 1 to 4.

6. The symptom or disorder is sleep-related, and the subject is administered with any one of claims 1 to 3. Administering the composition of claim 1 improves sleep quality in the subject.

5. The method according to claim 5.

7. The condition or disorder is related to vitality, and the subject is administered a method according to any one of claims 1 to 4.

2. The method of claim 1, wherein administering the composition of claim 1 improves the quality of vitality in the subject.

5. The method according to claim 5.

8. The condition or disorder is mood-related, and the subject is administered a treatment according to any one of claims 1 to 4. Administering the composition of claim 1 improves mood quality in the subject.

5. The method according to claim 5.

9. The symptom or disorder is pain-related, and the subject is administered with any one of claims 1 to 4. Administering the composition according to claim 5 relieves pain in the subject. The method described.

10. The symptom or disorder is memory-related, and the subject is administered with any one of claims 1 to 4. Administering the composition of claim 1 improves memory quality in the subject.

5. The method according to claim 5.

11. The condition or disorder is mentally related, and the subject is administered with any one of claims 1 to 4. Administering the composition of claim 1 improves the psychiatric disorder in the subject.

5. The method according to claim 5.

12. The condition or disorder is mentally related, and the subject is administered with any one of claims 1 to 4. Administering the composition according to claim 5 improves anxiety in the subject. The method described.

13. The condition or disorder is mentally related, and the subject is administered with any one of claims 1 to 4. Administering the composition of claim 1 improves cognitive function in the subject.

5. The method according to claim 5.

14. The symptoms or disorders include neuronal excitability, muscle contraction, membrane permeability, cell division, hormone secretion, bone The method of claim 5, which is associated with calcification or post-ischemic cell death.

15. The composition according to any one of claims 5 to 14, wherein the composition is administered to the subject in the form of a dietary supplement composition.

10. The method according to any one of claims 1 to 9.

16. The method of any one of claims 5 to 14, wherein the composition is administered orally to the subject. Law.

17. Prescription for treating and improving a human health condition in a subject administered a dietary supplement composition Use of the composition according to claims 1 to 4 for the manufacture of a dietary supplement composition.

18. Psychiatric disorders, anxiety, cognitive function, sleep, and vitality in subjects administered the dietary supplement composition and a claim for producing said dietary supplement composition for improving mood, pain, or memory. Use of the composition according to any one of items 1 to 4.

19. A composition for use in improving a health condition in a subject.

20. The effects of psychiatric disorders, anxiety, cognitive function, sleep, energy, mood, pain, or memory on subjects A composition for use in treating a condition or disorder.

Images